Gemcitabine: Pharmacology, Clinical Uses and Potential Side Effects

$95.00

Howard L. Reese (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Gemcitabine was synthesized in the 1980s at Lilly Research Laboratories (Eli Lilly and Co., Indianapolis, IN). It was initially developed as an antiviral agent, but it had an extremely narrow therapeutic index due to its cytotoxicity against the parental cell lines. As it presented wide activity against various solid tumors, it was then evaluated as an anticancer drug. This pyrimidine antimetabolite was firstly approved in 1996 by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

It is currently used for the treatment of many other malignancies such as lung cancer, breast cancer, lymphoma, bladder cancer, mesothelioma and ovarian cancer. This book discusses the molecular pharmacology, and the pharmacogenetics of gemcitabine. It also discusses the antineoplastic mechanism of gemcitabine on tumor cells; the systemic adverse effects; and provides detail on the clinical uses gemcitabine has on breast cancer. (Imprint: Nova Biomedical )

Clear

Details

Table of Contents

Preface

Chapter 1 – Gemcitabine: Molecular Pharmacology, Pharmacogenetics and Adverse Reaction Profile (pp. 1-62)
Begoña San José, Leocadio R. López-Giménez, Idoia Bilbao-Meseguer, Laura Serrano, Amaya De Basagoiti and Ainhoa Belaustegui (Cruces University Hospital, Barakaldo, Spain, and others)

Chapter 2 – Antineoplastic Mechanism of Gemcitabine on Tumor Cells with Different TP53/p53 Subtypes (pp. 63-78)
Glenda Nicioli da Silva and Daisy Maria Favero Salvadori (UFOP – Universidade Federal de Ouro Preto; Pharmacy School; Department of Clinical Analysis – Ouro Preto – MG – Brazil, and others)

Chapter 3 – Gemcitabine: Systemic Adverse Effects (pp. 79-96)
Abhijai Singh, M.D., Vinod K. Chaubey, M.D. and Lovely Chhabra, M.D. (Department of Internal Medicine, Shivam Hospital, Hoshiarpur, Punjab, India, and others)

Chapter 4 – Gemcitabine: Clinical Uses in Breast Cancer (pp. 97-104)
M. Mokrim, Y. Bensouda and H. Errihani (Medical Oncology Department, National Institute of Oncology, Rabat, Morocco)

Index

Additional information

Binding

,